Acer Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Acer Therapeutics

13/05/2023 03:02

* Acer Therapeutics Inc  ACER.OQ   ACER.O  is expected
to show no
change in quarterly revenue when it reports  results on May 15
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Acer Therapeutics
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months. ​
    * Wall Street's median 12-month price target for Acer
Therapeutics
Inc is $10​, above​ its last closing price of $0.76. ​​​

This summary was machine generated May 13 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated